Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q2 2019 · 10-Q
Revenue—
Net Income-$1.81M-$1.81MN/M vs Q2 2018 EPS Diluted-$0.03-$0.03N/M vs Q2 2018 Operating Cash Flowderived-$1,149,938N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
ended Jun 30, 2019 · filed Aug 14, 2019 · 45 d after period end